BOSTON (AI Forecast Terminal) Sat, Jan 30, '21 AI Forecast today took the forecast actions: In the context of stock price realization of AKBA Akebia Therapeutics is a decision making process between multiple investors each of which controls a subset of design variables and seeks to minimize its cost function subject to future forecast … The ex-dividend date of this dividend is Thursday, June 13th. Akebia Therapeutics (AKBA) stock price prediction is 3.128646 USD. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. And one last thing: the dividend yields are massive. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]. Akebia Therapeutics Inc stock is down -1.63% over the last 12 months, and the average rating from Wall Street analysts is a Buy.InvestorsObserver’s proprietary ranking system, gives AKBA stock a score of 78 out of a possible 100.. That rank is chiefly influenced by a short-term technical score of 97. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. Never miss a profitable trade. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts. Log In. Akebia Therapeutics stock forecast, AKBA price prediction: Buy or sell Akebia Therapeutics, Inc. shares? Shareholders of record on Friday, June 14th will be paid a dividend of $0.3675 per share on Monday, July 1st. Limited Time Only. Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2021-03-05 with daily … AKBA's revenues are forecast to grow slower (1.64% per year) than the US market average (14.8%) Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. During that period the price should oscillate between -7.35% and +13.91%. Given the current short-term trend, the stock is expected to rise 39.01% during the next 3 months and, with a 90% probability hold a price between $4.68 and $7.61 at the end of this 3-month period. Akebia Therapeutics Stock Forecast is based on your current time horizon. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. Akebia Therapeutics had a negative trailing twelve-month return on equity of 68.51% and a negative net margin of 126.86%. To see how Akebia Therapeutics, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: AKBA stock’s performance was -7.43% in the latest trading, and -59.51% in the past year, while Zoetis Inc Cl A (ZTS) has traded +0.1% on the day and positioned +12.61% higher than it was a year ago. Their forecasts range from $3.00 to $18.00. All rights reserved. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Forecast for Fri 05 Mar 2021 price 3.43 AKEBIA THERAPEUTICS INC stock price forecast for further price development down to -7.46% (time horizon: 1 day) and price target of 3.99 USD. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. With Akebia Therapeutics stock trading at $3.41 per share, the total value of Akebia Therapeutics stock (market capitalization) is $492.15M. Pinterest . AKEBIA THERAPEUTICS INC stock prediction: down to 3.99 USD AKBA stock price prognosis STOCK. High institutional ownership can be a signal of strong market trust in this company. Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. 14 brokerages have issued 12-month price objectives for Albemarle's sha… Shares of AKBA can be purchased through any online brokerage account. Want to see which stocks are moving? The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics employs 379 workers across the globe. What is AKBA's forecast return on equity (ROE) for 2021-2024? Get daily stock ideas top-performing Wall Street analysts. AKBA Stock Forecast - Get a free AKBA stock predictions and find out whether you should buy or sell AKBA stock. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Looking for new stock ideas? The U.S. House of Representatives voted to let the IMF circulate what could be a new elite-controlled reserve currency. AKBA Stock Forecast - Get a free AKBA stock predictions and find out whether you should buy or sell AKBA stock. 7 equities research analysts have issued 12-month price objectives for Akebia Therapeutics' stock. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating. Find out whether AKBA is in an … The AKBA stock was last observed … Is Akebia Therapeutics Stock a good buy in 2021, according to Wall Street analysts? Akebia Therapeutics does not have a long track record of dividend growth. 68.98% of the stock of Akebia Therapeutics is held by institutions. Around 10503412 of 144539000 changed hand on the market. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. Sr. VP, Chief Accounting Officer & Principal Accounting Officer, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month, Looking Into Akebia Therapeutics's Return On Capital Employed, Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference, Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript, Why Akebia Therapeutics Stock Is Plunging Today, Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates, Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors, Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights, Return On Capital Employed Overview: Akebia Therapeutics, Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference, Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference, Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options, AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal. Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA.". Learn everything you need to know about successful options trading with this three-part video course. In 2023, AKBA is forecast to generate $41,557,244,647 in revenue, with the lowest revenue forecast at $33,860,982,158 and the highest revenue forecast at $53,303,053,329. Akebia Therapeutics' management team includes the following people: I like to buy just one kind of stock and none other. Earnings vs Market: AKBA is forecast to become profitable over the next 3 years, which is considered above average market growth. Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.77) to ($0.72) per share. Sign Up. Analyst projections state that AKBA is forecast to be at a low of $3 and a high of $10. What is AKBA's earnings growth forecast for 2021-2023? During the day the stock fluctuated 7.29% from a day low at $3.29 to a day high of $3.53. Get the latest Akebia Therapeutics (AKBA) stock price quote with real-time news, financials, charts and other important investing information. Akebia Therapeutics Stock Forecast, AKBA stock price prediction. View analyst ratings for Akebia Therapeutics or view top-rated stocks. Akebia Therapeutics has received 392 “outperform” votes. Akebia Therapeutics last released its earnings data on February 24th, 2021. AKBA's Return on Equity is forecast to be low in 3 years (15.18%); analysts are not confident in the firm's ability to efficiently generate return on equity, AKBA is forecast to generate lower Return on Assets (5.83%) than the US Biotechnology industry average (22.14%), AKBA's revenue is forecast to grow at a rate of -0.71% per year, which is not exceptional, AKBA's revenues are forecast to grow slower (-0.71% per year) than the US Biotechnology industry average (65%), AKBA's revenues are forecast to grow slower (-0.71% per year) than the US market average (25.24%), On average, Wall Street analysts predict that. See what's happening in the market right now with MarketBeat's real-time news feed. AKBA 3.61 0.11 … View insider buying and selling activity for Akebia Therapeutics or view top insider-selling stocks. 7 analysts offering their recommendations for the stock have an average rating of 2.20, where 2 rate it as a Hold and 0 think it is a “Overweight”. NASDAQ 0.00%. Some companies that are related to Akebia Therapeutics include Myovant Sciences (MYOV), Dicerna Pharmaceuticals (DRNA), Zentalis Pharmaceuticals (ZNTL), NGM Biopharmaceuticals (NGM), Endo International (ENDP), Revance Therapeutics (RVNC), Kura Oncology (KURA), Seres Therapeutics (MCRB), Generation Bio (GBIO), Organogenesis (ORGO), Madrigal Pharmaceuticals (MDGL), Stoke Therapeutics (STOK), Ironwood Pharmaceuticals (IRWD), PMV Pharmaceuticals (PMVP) and Olema Pharmaceuticals (OLMA). Cancel. The official website for Akebia Therapeutics is www.akebia.com. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). DOW 0.00%. Fundamental company data provided by Zacks Investment Research. The consensus among Wall Street equities research analysts is that investors should "buy" Akebia Therapeutics stock. View which stocks are hot on social media with MarketBeat's trending stocks report. Top institutional investors include BlackRock Inc. (7.89%), Satter Management CO. L.P. (3.22%), Northern Trust Corp (1.21%), Dimensional Fund Advisors LP (1.21%), Dimensional Fund Advisors LP (1.14%) and Rice Hall James & Associates LLC (1.07%). View all of AKBA's competitors. Akebia Therapeutics, Inc. (AKBA) estimates and forecasts . Akebia Therapeutics has a P/B Ratio of 1.09. Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Get short term trading ideas from the MarketBeat Idea Engine. The … Our latest prediction for Akebia Therapeutics Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$. Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol \"ALB.\" Albemarle declared a quarterly dividend on Wednesday, May 8th. This suggests a possible upside of 166.6% from the stock's current price. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? AKBA Stock Analysis Overview What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 44, which is below average. Find out now with a free analysis on Akebia Therapeutics. On average, they expect Akebia Therapeutics' share price to reach $10.29 in the next year. AKBA stock news . The Stock opened at 3.99 with high and low of 3.86 and 4.56 respectively. The trend analysis tool will help you make a better prediction on the AKBA stock. View our earnings forecast for Akebia Therapeutics. And are mandated by law to make a profit. The AKBA stock will be analyzed using Smart Scan and the Trade Triangle technology. For the fiscal quarter endingMar 2021, the consensus EPS* forecast has decreased over the past week from -0.28 to -0.3 (7.14%) and decreased over the past month from -0.28 to -0.3 (7.14%). The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Twitter. Investors can use this forecasting interface to forecast Akebia Therapeutics historical stock prices and determine the direction of Akebia Therapeutics's future trends based on various well-known forecasting models. 100% FREE. Export data to Excel for your own analysis. Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021. Akebia Therapeutics Inc. (NASDAQ: AKBA) is 106.72% higher on its value in year-to-date trading and has touched a low of $2.99 and a high of $13.68 in the current 52-week trading range. This represents a $1.47 annualized dividend and a yield of 2.02%. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.20. WARNING: Trend forecast is still in the development phase and should be used with caution. What is AKBA's Earnings Per Share (EPS) forecast for 2021-2023? AKBA Stock Forecast. Akebia Therapeutics NASDAQ Updated Mar 13, 2021 12:47 AM. Analysts tracking AKBA have forecast the quarterly EPS to grow by -$0.36 per share this quarter, while the same analysts predict the annual EPS to hit -$1.26 for the year 2021 and up to -$0.69 for 2022. Another comparable company Takeda Pharmaceutical CO Ltd … In 2023, AKBA is forecast to generate $-37,103,134 in earnings, with the lowest earnings forecast at $-85,277,947 and the highest earnings forecast at $13,008,500. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.20. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Some bargain investors may see this as a … Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View which stocks have been most impacted by COVID-19. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View Akebia Therapeutics, Inc. AKBA investment & stock information. Learn more. 0 analysts have rated the stock as a Sell or Underperform. The trend analysis tool will help you make a better prediction on the AKBA stock. You may vote once every thirty days. Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. 8 brokers have issued twelve-month price objectives for Akebia Therapeutics' stock. Akebia Therapeutics has received a consensus rating of Buy. To see all exchange delays and terms of use please see disclaimer. AKBA Stock Predictions AKBA Stock Predictions. One share of AKBA stock can currently be purchased for approximately $3.61. The AKBA stock will be analyzed using Smart Scan and the Trade Triangle technology. Akebia Therapeutics 3.61 0.11 (2.96%) Watch. Revenue vs Market: AKBA's revenue (13.8% per year) is forecast to grow faster than the US market (10.1% per year). Facebook. AKBA Stock Predictions. Its exchange rate could effectively devalue the U.S. dollars in your pocket and your savings. MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Please log in to your account or sign up in order to add this asset to your watchlist. How can you protect your money and all you’ve worked for from this reset? The Akebia Therapeutics stock forecast is 3.128646 USD for 2022 March 04, Friday; and 3.007 USD for 2026 March 04, Wednesday. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. In this case, analysts estimate an annual EPS growth of -0.55% for the year and -0.45% for the next year. Since then, AKBA stock has decreased by 48.0% and is now trading at $3.61. In order for the stock price to hit the forecast high, the stock would need to surge +125.23% from its current level, while the stock would need to crash -32.43% from its current level to reach the projected low. According to analysts' consensus price target of $9.63, Akebia Therapeutics has a forecasted upside of 166.6% from its current price of $3.61. Akebia Therapeutics has a market capitalization of $554.14 million and generates $335 million in revenue each year. Akebia Therapeutics, Inc. (AKBA) projections and forecasts . Learn about financial terms, types of investments, trading strategies and more. S&P 500 0.00%. (NASDAQ: AKBA) Akebia Therapeutics currently has 144,538,894 outstanding shares. WhatsApp. In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock. Rooms Shows Rankings Earnings Calendar Shop. Compare Top Brokerages Here. AKBA Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. You can opt out at any time. Should I buy or sell AKBA? See What Biden and the Democrats Just Did To YOUR Money. Do Not Sell My Information. Akebia Therapeutics has only been the subject of 3 research reports in the past 90 days. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Not a single company in this entire industry has ever gone out of business—ever. Should I buy or sell AKBA? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. This suggests a possible upside of 202.5% from the stock's current price. Trending now. Learn more. Real-time trade and investing ideas on Akebia Therapeutics AKBA from the largest community of traders and investors. Vote “Outperform” if you believe AKBA will outperform the S&P 500 over the long term. (Add your “underperform” vote.). The price/earnings ratio is: - and earning per share is -2.97. AKBA Stock Forecast - Is AKBA a buy or sell? View Albemarle's Dividend History. The Akebia Therapeutics stock price fell by -2.20% on the last day (Monday, 8th Mar 2021) from $3.41 to $3.33. AKBA's rank also includes a long-term technical score of 94. Shameful! View our full suite of financial calendars and market data tables, all for free. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. By. To hit the forecast high, the stock’s price needs a +194.99% upsurge from its latest level, while the stock would need to tank -11.5% for it to hit the projected low. Identify stocks that meet your criteria using seven unique stock screeners. Only 2.55% of the stock of Akebia Therapeutics is held by insiders. Scan for strong stocks. AKBA Stock Forecast: All the More Reason to Consider Akebia Therapeutics Inc. (AKBA) Now. Our Accessibility Statement Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings data on Wednesday, February, 24th. Free Signup : Top 50 Stocks Top 10 Penny Stocks Bullish Engulfing Scanner … On average, they anticipate Akebia Therapeutics' share price to reach $9.63 in the next year. AKBA’s announcement was unexpected and the sudden plunge of its stock price reflects that. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. Their forecasts range from $3.00 to $18.00. Akebia Therapeutics has received 53.99% “outperform” votes from our community. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. AKBA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, BlackRock Inc., SG Americas Securities LLC, Engineers Gate Manager LP, Alliancebernstein L.P., Virginia Retirement Systems ET AL, and Dynamic Technology Lab Private Ltd. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, and Maxine Gowen. Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). 5 of the analysts rate the stock as a “Buy”. What is AKBA's revenue growth forecast for 2021-2023? Akebia Therapeutics has generated ($1.63) earnings per … View institutional ownership trends for Akebia Therapeutics. These unique companies are almost always monopolies. ), Akebia Therapeutics has received 334 “underperform” votes. Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. Should I buy or sell AKBA? (Add your “outperform” vote. The P/E ratio of Akebia Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The price has fallen in 6 of the last 10 days and is down by -18.98% for this period. High Growth Earnings: AKBA's is expected to become profitable in the next 3 years. Akebia Therapeutics Inc. Stock Price Forecast, "AKBA" Predictons for2021 © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. © American Consumer News, LLC dba MarketBeat® 2010-2021. According to the market data, Akebia Therapeutics Inc. (AKBA) stock price is $3.405 and the 52 weeks low is $2.09, which means the Akebia Therapeutics Inc. stock price is down -62.42% in the last 12 months. In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Akebia Therapeutics does not currently pay a dividend. AKBA stock was purchased by a variety of institutional investors in the last quarter, including Satter Management CO. L.P., Renaissance Technologies LLC, Norges Bank, Principal Financial Group Inc., Nisa Investment Advisors LLC, Russell Investments Group Ltd., Tudor Investment Corp Et Al, and Bank of New York Mellon Corp. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke. According to analyst projections, AKBA’s forecast low is $3 with $10 as the target high. Andrew Francis - July 7, 2020. View real-time stock prices and stock quotes for a full financial overview. Some Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Just Made A Major Cut To Next Year's Estimates, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. View insider buying and selling activity for Akebia Therapeutics or or view top insider-buying stocks. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Receive a free world-class investing education from MarketBeat. Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). View Akebia Therapeutics' earnings history. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. What is AKBA's forecast return on assets (ROA) for 2021-2024? This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.